Belgium· BE-AMP-SAM660629-00
Lupkynis 7.9 mg
A voclosporin product containing voclosporin, registered in Belgium by Otsuka Pharmaceutical Netherlands. The same ATC class is registered in 14 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Voclosporin is registered in 14 of 19 countries.
Countries holding a registration under ATC L04AD03 (voclosporin), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 9 of them publish a price we can compare per daily dose
Voclosporin · ATC L04AD03
14 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of voclosporin costs, country by country.
Normalised to the WHO defined daily dose (47.4 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Voclosporin · price per daily dose (47.4 mg)
USD · FX 28 Sept 2026
- CH Switzerland$30.96
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Voclosporin
- Manufacturer
- Otsuka Pharmaceutical Netherlands
- Country
- Belgium (BE)
- ATC code
- L04AD03
- ATC class
- Voclosporin
- Defined daily dose
- 47.4 mg, O
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
- be_apb4663746
- be_apb7742620
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Voclosporin in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaLUPKYNISOtsuka Pharmaceutical Netherlands B.V., Amsterdam
- SpainLUPKYNIS 7,9 MG CAPSULAS BLANDASOtsuka Pharmaceutical Netherlands B.V.
- FinlandLupkynisOtsuka Pharmaceutical Netherlands B.V.
- IrelandLupkynis 7.9 mg soft capsulesOtsuka Pharmaceutical Netherlands B.V.
- IcelandLupkynisOtsuka Pharmaceutical Netherlands B.V.*
- NorwayLupkynisOtsuka Pharmaceutical Netherlands B.V.
- PolandLupkynisOtsuka Pharmaceutical Netherlands B.V.
- SwitzerlandLupkynis 7,9 mg, WeichkapselOtsuka Pharmaceutical (Switzerland) GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Lupkynis
- Liechtenstein · Lupkynis
- Norway · Lupkynis
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/854c8121-654d-4fd9-9ab7-ae92cee69146 GET /v1/drugs/854c8121-654d-4fd9-9ab7-ae92cee69146?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Capsule, soft",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Lupkynis 7.9 mg",
"name_fr": "Lupkynis 7.9 mg",
"name_nl": "Lupkynis 7.9 mg",
"amp_code": "SAM660629-00",
"strengths": [
"7.9000",
"7.9000",
"7.9000",
"21.6000",
"21.6000",
"28.7000",
"28.7000"
],
"pack_count": 2,
"substances": [
"Voclosporin",
"Ethanol",
"Glycerol",
"Sorbitol",
"Polysorbate 40"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Voclosporin",
"authorisation_numbers": [
"EU/1/22/1678/001",
"EU/1/22/1678/002"
]
}See everything about voclosporin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.